Is Wegovy Going Up? What Dose Increases Actually Mean

What is the Wegovy dose schedule, and how far does it go?

Wegovy (semaglutide) follows a step-up schedule prescribed by your clinician. It begins at 0.25 mg weekly, a dose that exists mainly to let your digestive system settle in, not to produce significant weight loss. From there, most patients move through 0.5 mg, 1.0 mg, 1.7 mg, and eventually 2.4 mg, spending roughly a month at each level. The NHS semaglutide medicines page sets out the full step sequence for patients.

In early 2026 the picture changed. The MHRA approved a 7.2 mg maintenance dose in January 2026, initially delivered as three 2.4 mg pens used in a single week. Then, on 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg pen (one pre-set injection per week) for adults with a BMI of 30 or above. If you're already stable on 2.4 mg and still want to explore whether the higher dose suits you, that conversation starts with your prescriber. No online pharmacy should be moving your dose upward without a clinical review first.

So: yes, Wegovy does go up, significantly. The full picture of what Wegovy goes up to covers the new 7.2 mg option in more detail, including how the titration to that level works.

How does a prescriber decide it's time to increase the dose?

The decision to step up isn't automatic. Your prescriber looks at two things: how you're tolerating the current dose, and whether it's producing a meaningful clinical response. Tolerability matters most at the early steps. Nausea, loose stools, or persistent reflux are signals that your body may need another four weeks at the same level before going higher. Pushing the dose up while those symptoms are active almost always makes them worse. There's no race to the top.

Later in the schedule, if you've been stable on a dose for several weeks without significant side effects but Wegovy doesn't seem to be doing anything in terms of appetite or weight, that's often the clinical prompt to move up. The STEP 1 trial (published in the New England Journal of Medicine) showed that the greatest average weight reduction with semaglutide 2.4 mg came over 68 weeks, with the titration period forming a meaningful part of that timeline. Results are rarely linear week by week.

A prescriber at a regulated pharmacy reviews your situation before each dose change. At nume, that review happens before every repeat order, a real clinician reads your responses, not software.

What side effects tend to appear when the dose goes up?

Most people notice the most side effects either when they start Wegovy or when the dose increases. Nausea is the most commonly reported, followed by changes in bowel habits (diarrhoea or constipation) and occasionally vomiting. These effects tend to be most pronounced in the first few days after the increase and usually ease within a week or two as the body adapts. Fatigue, mild headaches, and indigestion can also flare at transition points.

Severe or persistent symptoms are worth taking seriously. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but uncommon side effect of GLP-1 medicines: the specific warning sign is severe stomach pain that radiates to the back, with or without vomiting, if that happens, stop the injection and seek urgent medical help. You can report any suspected side effect through the MHRA Yellow Card scheme.

Vomiting that's frequent enough to disrupt daily life is a different problem from run-of-the-mill nausea. What to do when Wegovy makes you vomit explains how to manage it and when to contact your prescribing team.

Does a higher dose always mean better results?

Not automatically, and it's worth understanding why. The dose schedule exists because semaglutide's effect on appetite becomes stronger as the level rises, but so does the potential for side effects. Some people find their appetite is well controlled at 1.7 mg and tolerate 2.4 mg poorly. In those cases, staying at a lower effective dose is a reasonable clinical position, not a failure.

For others, the jump to 7.2 mg genuinely changes the picture. Trial data at that dose has shown average weight reduction of around 20.7% over 72 weeks, which is closer to the results seen with tirzepatide at its highest level. Whether that higher dose is appropriate for you depends on your BMI, your response so far, and your tolerability profile, all factors your prescriber weighs up. Think of it less as a ladder you must climb to the top, and more as a calibration to find the dose your body responds to without making every morning miserable.

If you're weighing up your options or wondering whether to try a different treatment altogether, our weight-loss treatment overview covers what's licensed in the UK right now. And if you're thinking about pausing Wegovy and coming back to it later, there's useful context on restarting Wegovy after a break, including what your prescriber will consider before you step back up the dose. The cost of treatment at different stages is something our guide to where to buy Wegovy in the UK addresses, including what a legitimate price should include.

Our clinical team reviews every consultation personally, if you'd like to discuss where you are with your current dose, or start treatment for the first time, speak to our prescribers through a free consultation.